Background-The upstream transcription factor 1 (USF1) gene is associated with familial combined hyperlipidemia, the most common genetic dyslipidemia in humans, as well as with various dyslipidemic changes in numerous other studies. Typical of complex disease-associated genes, neither the explicit mutations have been described nor the functional consequences for risk allele carriers been reported at the cellular or tissue level. Methods and Results-In this study, we aimed at describing the molecular mechanism through which the strongest associating intronic single-nucleotide polymorphism variant in USF1 is involved in the development of dyslipidemia. The effects of the risk variant on gene expression were studied in 2 relevant human tissues, fat and muscle. Global transcript profiles of 47 fat biopsies ascertained for carriership of the risk allele were tested for differential expression of known USF1 target genes as well as for broader effects on the transcript profile. Allelic imbalance of USF1 in fat was assessed using a quantitative sequencing approach. The possible allele-specific effect of insulin on the expression of USF1 was studied in 118 muscle biopsies before and after a euglycemic hyperinsulinemic clamp. The risk allele of single-nucleotide polymorphism rs2073658 seems to eradicate the inductive effect of insulin on the expression of USF1 in muscle and fat. The expression of numerous target genes is in turn perturbed in adipose tissue. Conclusions-In risk allele carriers, a defective response of USF1 to insulin results in the suboptimal response of relevant target genes that contributes to the enhanced risk of developing dyslipidemia and coronary heart disease. (Circ Cardiovasc Genet. 2009;2:522-529.)
T he upstream transcription factor (USF1) is a ubiquitously expressed transcription factor shown to regulate numerous genes involved in lipid and glucose metabolisms. As a homodimer or a heterodimer with the related USF2, it binds an E-box element (consensus sequence CACGTG) within the glucose/insulin responsive element in the promoters of the downstream genes, activating their transcription. 1, 2 We have previously identified USF1 as the first gene associated with the dyslipidemia observed in familial combined hyperlipidemia (FCHL), 3 the most common genetic dyslipidemia in humans. 4, 5 This finding has since been replicated in multiple FCHL 6 -9 as well as other dyslipidemic cohorts. 10 -13 Moreover, risk alleles have been found to associate with cardiovascular disease risk and mortality. 14 -17 The association of USF1 variants with type 2 diabetes (T2D) has been more debatable, with both negative 18, 19 and positive 20, 21 associa-tions reported. The strongest associating single-nucleotide polymorphism (SNP) (usf1s2) of the original study (and most of the subsequent studies) is likely to be functionally relevant, because it is located in a conserved sequence and shown to bind nuclear proteins. 22 However, no data on any functional defects in the USF1 protein itself or the dynamics of its expression have been published to date, largely owing to the fact that no coding mutations have been found and that the basal transcript levels of USF1 in the tissues studied have been too low for detecting any quantifiable changes in transcript levels.
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It has been suggested that the usf1s2 polymorphism in intron 7, which shows the strongest association with the dyslipidemic phenotype may activate an alternative promoter, resulting in a shorter USF1 protein, lacking the transactivation domain. 23 In vitro, this phenomenon has been shown to result in a USF1 molecule that acts as a dominant inhibitor. 24, 25 However, in our investigation, no such alternative promoter usage was observed. 22 Since the identification of USF1 as the gene associating with FCHL, numerous studies have been performed to establish its role in other related disorders of lipid and glucose metabolisms and their component traits. Although the usf1s2 variant defines the risk allele that has been associated with changes in highly relevant and interesting dyslipidemia component traits, such as antilipolytic insulin sensitivity, 13 in vitro catecholamine-induced lipolysis, 10 and response of peak glucose or triglycerides to oral glucose and fat tolerance tests, 11 respectively, the actual molecular or cellular mechanisms behind the differences in the dynamics of USF1-related processes remain unknown.
This study was undertaken to explore the functional relevance of the specific allelic variant of USF1, underlying the observed associations to various dyslipidemic parameters. The relationship between the disease-associated usf1s2 variant and the expression of USF1 and its target genes was investigated in individuals carrying different allelic combinations, and in 2 human tissues, adipose and skeletal muscle, both relevant target tissues for insulin resistance known to influence lipid metabolism. 26 Because an effect of allelic variants of USF1 on the postprandial response has been implied, 11 the muscle biopsies were obtained before and after a hyperinsulinemic, euglycemic clamp to allow for identification of possible changes in the dynamics of USF1 function.
Methods

Study Subjects
Subjects belonging to Finnish dyslipidemic FCHL and low highdensity lipoprotein (HDL) families were genotyped and described in our earlier studies. 3 Subjects from these 2 cohorts ascertained for their usf1s2 (rs2073658) genotype were asked to participate in a fat biopsy. Subjects were selected so as to obtain equal number of carriers of the risk allele (G) and the rarer AA homozygotes and to keep the clinical characteristics such as age, body mass index (BMI), and sex comparable between the groups (Table 1) . Altogether, 47 subjects were biopsied, 14 with genotype GG, 10 with genotype GA, and 23 with genotype AA. Carriers of the risk allele were analyzed collectively and compared with nonrisk genotype AA individuals.
Subjects for the muscle biopsy were identified through The Danish Twin Register and selected as described previously. 27, 28 A total of 98 young (aged 25 to 32 years) and elderly (aged 58 to 66 years) twin pairs were included in a clinical examination. We were able to obtain both genotype and skeletal muscle USF1 mRNA expression levels from 71 of the twin pairs (58 younger monozygotic, 32 younger dizygotic, 22 elderly monozygotic, and 30 elderly dizygotic twins; Table 2 ). Zygosity was determined by polymorphic genetic markers. The twin sample used here provides unique advantages for genetic analyses, because using monozygotic twins essentially provides 2 phenotypes for 1 genotype thereby minimizing the effect of environmental noise on expression levels.
Tissue Biopsies
Fat biopsies were collected by a needle aspiration biopsy of periumbilical subcutaneous fat under local anesthesia. Biopsies were frozen in liquid nitrogen and stored at Ϫ146°C for later analysis. The Ethical Committee of the Department of Medicine, Helsinki University Central Hospital approved the study. All subjects gave their written informed consent before participation in the study, which was performed in accordance with the Helsinki declaration.
Muscle biopsies were obtained from the vastus lateralis muscle under local anesthesia, using a modified Bergström's needle (including suction) before and after a 2-hour euglycemic hyperinsulinemic clamp. Biopsies were immediately frozen in liquid nitrogen and stored at Ϫ80°C for later analysis. The study was approved by the regional ethics committee.
Expression Analyses in Adipose Tissue
Total RNA was extracted using the RNeasy Lipid Mini Kit (Qiagen, Dusseldorf, Germany) according to the manufacturer's instructions. The quality of RNA was analyzed using the 2100 Bioanalyzer platform (Agilent Technologies, Palo Alto, Calif., USA). Two micrograms of total RNA were treated according to conventional Affymetrix eukaryotic RNA-labeling protocols (Affymetrix, Santa Clara, Calif). Fifteen micrograms of biotin-labeled cRNA was fragmented according to the Affymetrix eukaryotic sample protocol. Hybridization, staining, and washing of the Affymetrix U133 Plus 2.0 chips were performed using the Affymetrix Fluidics Station 450 and Hybridization Oven 640 under standard conditions. Before analysis, raw expression data (.CEL files) were normalized using the GCRMA algorithm. Analysis of the adipose tissue expression data was done using the GeneSpring GX 7.3 expression analysis software (Agilent Technologies). 
Allelic Imbalance Assay
Genomic and cDNA from 11 individuals heterozygous for the usf1s1 (rs3737787) SNP (also heterozygous for the usf1s2 SNP due to complete linkage disequilibrium) were used for the sequencingbased allelic imbalance assay. Adipose tissue-derived RNA was extracted using the RNeasy kit (Qiagen) according to the manufacturer's instructions. A total of 1 g of RNA were used for synthesis of cDNA with the Taq-Man Gold RT-PCR kit, according to the manufacturer's instructions. Polymerase chain reaction (PCR) primers for amplifying a 497 bp stretch of USF1 including the SNP usf1s1 (rs3737787) in the 3Јuntranslated region (UTR) of the gene were designed using Primer 3 software (Steve Rozen and Helen J. Skaletsky). PCR primers were ordered from Proligo (sequences available on request). All sequencing reactions were run in triplicate, and the gDNA samples used to establish the expected 50:50 heterozygote profiles were run simultaneously on the same sequencing plate as the cDNA samples. Sequencing was performed using the ABI3730 xl DNA Analyzer and BigDye 3.1 chemistry (Applied Biosystems, Foster City, Calif), and the GeneMapper 4.0 software (Applied Biosystems) was used for calling the allele peak heights. Allelic imbalance was defined as a deviation in the cDNA sample from the 50:50 heterozygote ratio observed in the gDNA sample. Statistical significance was determined using the 1-sample t test with a population mean of 1. PϽ0.05 was considered significant.
Real-Time PCR Measurements of USF1 mRNA in Muscle Tissue
Extraction of total RNA from the muscle biopsies was performed with the TRI reagent (Sigma-Aldrich, St. Louis, Mo). The cDNA was synthesized using RevertAid H Minus M-MuLV Reverse Transcriptase (Fermentas, Burlington, Ontario, Canada) and random hexamer primers. Real-time PCR was performed using the ABI PRISM 7900 Sequence Detection System (Applied Biosystems) according to the manufacturer's instructions. Primers and probe for USF1 mRNA quantification were ordered as a ready to use mix of primers and an FAM-labeled probe (Hs00273038_m1, Applied Biosystems). Cyclophilin A was used as an endogenous control to standardize the amount of cDNA added to the reactions using a ready to use mix of primers and a VIC-labeled probe (Applied Biosystems). All samples were run in duplicate, and data were calculated using the standard curve method and expressed as a ratio to the Cyclophilin A reference.
Statistical Analyses
Analyses of global gene expression in adipose tissue were performed using the GeneSpring GX 7.3 expression analysis software (Agilent Technologies). All other statistical analyses of adipose biopsies were performed using SPSS 11.0 for Windows (SPSS Inc, Chicago, Ill). In the test for differential expression of USF1 target genes, the reported P value is that for a nonparametric Mann-Whitney U test. A P value of Ͻ0.05 was considered significant. The P values presented in Table 3 have not been corrected for multiple testing. A Bonferroni correction would require the multiplying of all P values by 32, requiring Pϭ0.0016 for surviving this correction. However, this correction is far too conservative for gene-expression values because they are not independent of each other. A majority of the transcripts analyzed here are highly correlated with each other, and therefore, uncorrected P values are presented.
Expression data for the muscle biopsies are presented as meanϮSEM. Paired comparisons of muscle USF1 mRNA expression before and after insulin clamp were performed using the parametric paired t test. Other comparisons were performed using proc mixed (ANOVA) in the SAS system for Windows (SAS Institute Inc, Cary, NC), where we adjusted for gender (apart from when analyzing differences between men and women) and intratwin-pair relationship by including a random effect term for a twin-pair membership and a fixed-effect term for zygosity in the full model (P a values).
Results
USF1 Transcript Levels in Muscle Are Affected by Insulin in an Allele-Specific Manner
We wanted to determine whether the usf1s2 allele had an influence on the basal-expression level of USF1 or on the dynamics of its expression in response to hyperinsulinemia. In addition to the adipose tissue and the liver, muscle is an important target tissue of insulin action. Therefore, USF1 transcript levels were determined in skeletal muscle biopsies obtained before and after a euglycaemic hyperinsulinemic clamp from 142 young and elderly twins.
In agreement with our earlier findings in the adipose tissue samples, 22 neither were there any differences in basal USF1 expression observed between individuals carrying different alleles of the SNP usf1s2 (rs2073658; 0.88Ϯ0.04 [GGϩGA individuals, nϭ113] versus 0.74Ϯ0.13 [AA individuals, nϭ22], P a ϭ0.5) nor were there any age-related differences in the USF1 expression. However, there was a gender difference with men displaying significantly higher USF1 mRNA levels , P a ϭ0.02, for basal and postclamp USF1 mRNA levels, respectively). However, a clear difference was observed between individuals carrying different allelic combinations in the response to insulin. The individuals homozygous for the nonrisk allele responded to the hyperinsulinemia by strongly upregulating USF1 expression (0.76Ϯ0.15 versus 1.14Ϯ0.18, Pϭ0.002, nϭ19 for the pre-and postinsulin measurements, respectively), whereas those carrying the risk allele failed to show any signs of the inductive effect of insulin (0.89Ϯ0.04 versus 0.87Ϯ0.04, Pϭ0.45, nϭ99 for the pre-and postinsulin measurements, respectively; Figure 1 ).
Allelic Imbalance of USF1 in Adipose Tissue
The very low expression level of USF1 in adipose tissue has made any comparisons of quantifiable differences between samples inaccurate or even impossible. To compare the levels of allelic transcripts of USF1 transcript in adipose tissue, we selected samples from heterozygote individuals and measured the allelic transcripts for the risk and nonrisk alleles by means of quantitative sequencing. 29 Primers were designed to amplify the 3ЈUTR of USF1 containing the SNP usf1s1 (rs3737787) from both genomic DNA and the cDNA (transcribed from RNA of fat biopsies) from 11 individuals heterozygous for the variant (also heterozygous for the SNP usf1s2 because of perfect linkage disequilibrium). Sequencing of the genomic DNA yielded equal-sized peak heights in the sequencing readout, whereas sequencing of the cDNA yielded unequal peak heights in 9 of 11 fat samples, suggesting allelic imbalance (Figure 2A) . The risk allele of USF1 was expressed at Ϸ20% lower level compared with the nonrisk allele in the samples exhibiting allelic imbalance (Pϭ0.035, 2 test; Figure 2B ). We confirmed the reliability of our quantitation method by producing a standard curve consisting of mixed samples with controlled and varying amounts of DNA from 2 samples homozygous for the opposite alleles. The DNAs were carefully measured and mixed to produce heterozygous samples with known levels of the allele-specific target sequence in the sample.
Given the distinct allele-specific effect of insulin on the steady-state transcript levels of USF1 in the muscle biopsies, we tested whether the observed variation between samples in the degree of allelic imbalance in fat would also be affected by insulin. Indeed, the individual sample with the highest fasting serum insulin also had the highest degree of allelic imbalance in the adipose tissue. A trend for the correlation of fasting insulin with allelic imbalance of the USF1 transcript was observed but did not reach statistical significance. Importantly, the direction of the trend conformed to what could have been predicted from the observed effect in muscle; ie, the nonrisk, or insulin-sensitive, allele (A) was increased in comparison with the risk allele (G) with higher serum insulin concentration.
Multiple USF1 Target Genes are Differentially Expressed
The ultimate mechanism of USF1-associated dyslipidemia is assumed to ensue through the altered expression of relevant target genes involved in lipid and glucose metabolisms. Our earlier work showed that individuals carrying the risk allele of the critical SNP usf1s2 had differential expression of pertinent USF1 target genes in fat biopsies. 22 In a new sample set of 47 fat biopsies from individuals ascertained for the carrier status of the usf1s2 polymorphism (from Finnish dyslipidemic FCHL and low-HDL families), we monitored the known USF1 target genes for differential expression using the Affymetrix U133 Plus 2.0 array. Of the 54 known USF1 target genes available for inspection on the array, 32 were expressed in the adipose tissue at a sufficiently high level to produce reliable signals. Comparing 24 risk-allele (G) carriers of the SNP usf1s2 with 23 nonrisk-allele homozygotes (AA) revealed nearly one third (10 of 32) of these USF1 target genes differentially regulated (nonparametric Mann-Whitney U test PϽ0.05). Four genes were upregulated and 6 were downregulated in the risk-allele carriers ( Table 3 ). Of immediate interest was the observation that although the upregulated genes contained genes involved with the inflammatory response, the downregulated genes were those mostly involved in lipid metabolism-findings that agree well with the dyslipidemic state.
Especially, prominent effect of the usf1s2 risk-allele carrier status was observed on the transcript levels of the gene coding for acetyl-CoA carboxylase ␤ (ACACB). Expressed as a fold change, the risk-allele carriers had ACACB transcript levels only 68% of that observed in the nonrisk-allele homozygotes (Pϭ1.65ϫ10 Ϫ4 ). The transcript levels of ACACB in this sample were correlated with sex, BMI, waist-to-hip ratio, insulin, HDL cholesterol, and usf1s2 allele, but in a multiple correlation analysis, only the usf1s2 allele and BMI variables entered the final model, with an adjusted R 2 of 0.433 (PϽ0.001). Of the 2 variables, the usf1s2 allele was the strongest determinant in the equation explaining the variation of ACACB expression in our sample.
As there was an observable sex-specific difference in the abundance of USF1 transcript, as well as a small difference in the sex distribution between groups, we also tested the other target genes identified as differentially expressed between different usf1s2 allele carriers for possible gender-specific effects in the fat biopsies. In an ANOVA analysis, testing for the effects of usf1s2 allele, age, BMI, and gender only the expression of MAP2K1 was influenced by gender (Pϭ0.007). The effect of gender was somewhat less significant than the effect of the usf1s2 risk allele (Pϭ0.003).
Regional Genes not Coexpressed
We wanted to exclude the possibility of a strong cisregulatory element in the vicinity of the USF1 gene that could have an impact on the allelic transcript levels of the gene. To test for possible coregulation of genes in the physical vicinity of USF1, nonsupervised clustering of the expression profiles of 20 neighboring genes (15 of which were expressed in fat), flanking total of 410 kB of genomic DNA, was performed. No evidence of regional coregulation could be detected, because no similar clusters were observed. These data suggest that the existence of a strong cis-regulatory element potentially affecting multiple regional genes is unlikely. Moreover, the expression changes associated and most probably caused by the usf1s2 variant are limited to the USF1 gene.
Global Transcript Levels in Adipose Tissue Expose Some Potential, Previously Unidentified USF1 Targets
The list of known USF1 target genes is growing, linking this transcription factor to an increasing number of pathways. With the observed influence of the usf1s2 allele on the expression of so many of the known USF1 targets, we wanted to test for this effect on the global transcript profile in the adipose tissue. To this end, we first generated a list of genes differentially expressed between the usf1s2 risk-allele carriers and nonrisk-allele homozygotes. Of the 54 613 probes present on the array, 30 155 passed initial filtering of the data set to exclude those genes with unreliably low-signal intensity. Of this set, 4847 probes (representing 3693 unique gene products) were differentially expressed between the genotype groups (Welch t test PϽ0.05; online-only Data Supplement). To test for the possible role of USF1 in controlling the expression of these genes, we used the oPOSSUM software. 30 This software combines a database of conserved transcription factor binding sites in human and mouse promoters with statistical methods to test whether the binding sites of certain transcription factors are overrepresented in a given gene set. Of the 3693 genes input, the software was able to analyze 2897 and among this list of differentially expressed genes, binding sites for USF1 were significantly enriched (Pϭ2.8ϫ10 Ϫ5 ). This implies a large-scale effect of the usf1s2 allele on the expression of numerous USF1 target genes that still remain to be identified.
Discussion
In this study, we wanted to examine the link between the identified disease-associated variants within the USF1 gene, tagging the risk allele of this gene, and their potential influence on the dynamics of its expression, and consequently the downstream effects that could explain the molecular pathology behind common dyslipidemias such as FCHL. The investigations were performed using 2 relevant target tissues, namely fat biopsies from Finnish dyslipidemia families and muscle biopsies from the Danish twin cohort. We observed that after a 2-hour insulin challenge, the dyslipidemiaassociated allelic variant of USF1 had a significant effect on USF1 transcript levels in muscle. Only the nonrisk-allele homozygotes (AA) responded to the hyperinsulinemia with increased transcript levels. An effect of the same allelic variant was also observed in adipose tissue, in the form of allelic imbalance, with the risk allele being underrepresented at the transcript level. We also identified numerous relevant USF1 target genes that were differentially expressed in adipose tissue of individuals carrying the risk allele, most notably among them ACACB, an important regulator of fatty acid oxidation. 31 Our results describe how a noncoding variant in the transcription factor USF1, perhaps the best replicated finding behind common dyslipidemia, predisposes a large portion of the population carrying the risk allele through a mechanism involving insulin-dependent transcriptional regulation of the transcription factor itself.
Allelic imbalance assays require the variant under scrutiny to be transcribed, hence making intronic variants untestable. However, if a variant located in a transcribed sequence is in complete LD with the intronic variant of interest, it can serve as a proxy for the latter. This is the case with the riskassociated variant of USF1, usf1s2 (rs2073658) located in intron 7 and the variant usf1s1 (rs3737787) located in the 3ЈUTR of USF1. These variants are in complete LD, with r 2 ϭ1, allowing for monitoring for possible effects of the intronic usf1s2 variant. We have published previously functional data for the usf1s2 variant: the short-conserved DNA sequence containing this SNP specifically binds nuclear protein(s), however, this binding is seemingly not affected by the variant in vitro. 22 With the present data, it is tempting to hypothesize that the proteins binding to this critical intronic sequence are related to the insulin responsiveness of the gene. With the complete LD, however, the possible functional role of the 3ЈUTR usf1s1 variant cannot be excluded.
It seems that the control of USF1 by insulin at the transcriptional level is a more recently acquired trait, because the insulin-sensitive allele of USF1 (the usf1s2 A allele) is the minor allele with a 34% frequency in the Finnish population, whereas the allele unresponsive to insulin represents the ancestral allele, shared by chimpanzees. To our knowledge, this is the first indication in human samples that insulin is not only critical for the phosphorylation of the dimeric USF1 32 but also seems to regulate the transcription of this gene, critical for lipid and glucose metabolisms.
The apparent changes in the transcript levels of relevant USF1-target genes in adipose tissue fit well with the observed influences of USF1-risk variants on various aspects of lipid metabolism: antilipolytic insulin sensitivity associated with the A allele of usf1s2 13 here reported to be itself insulin sensitive, in vitro catecholamine-induced lipolysis, 10 and response of peak glucose or triglycerides to oral glucose and fat tolerance tests, respectively. 11 As discussed, 13 the lack of agreement over the involvement of USF1 variants in T2D 18, 19, 21 may be due to the fact that although USF1 regulates numerous genes involved in lipid metabolism, the list of genes related to glucose metabolism is much shorter. Thus, changes in USF1 may have smaller effects on glucose metabolism and T2D. This is supported by our current findings of the effect on USF1 target genes in adipose tissue, among which lipid metabolism genes predominate. However, variation at USF1 may modify the risk for T2D risk in exceptional families ascertained for high incidence of T2D as reported in Chinese families. 33 In addition to the observed effect of the usf1s2 allele on the known USF1 target genes, the significant enrichment of USF1 binding sites in the promoters of differentially expressed genes identified in a global analysis strengthens further the case that the usf1s2 allele carries functional significance, which is detectable in the expression of its target genes.
Especially, prominent was the USF1 genotype-dependent expression of the USF1-target gene ACACB 34 in fat. The ACACB protein regulates mitochondrial fatty acid oxidation by synthetizing malonyl-CoA, which is an allosteric inhibitor of carnitine palmitoyl transferase 1. 31, 35 Depletion of ACACB 36 or inhibition of its activity by phosphorylation 35 results in increased fatty acid oxidation. ACACB is reported to be primarily expressed in heart and skeletal muscle tissue and to a lesser extent in liver, 36 but in our fat biopsies, it was clearly among the top 1% of most highly expressed genes. Although the whole-body ACACB knockout mice are reportedly leaner and have a higher insulin sensitivity, 37 we observed a highly significant negative correlation of ACACB transcript levels with BMI in our adipose tissue samples (Pearson Ϫ0.536, Pϭ0.0001). In addition to highlighting the differences between mice and men, these results also suggest that ACACB may have a somewhat different mechanism of action in adipose cells, a tissue perhaps overlooked so far. The significantly lowered ACACB expression in the adipose tissue of USF1 risk-allele homozygotes in our samples seems to be a dyslipidemia-and obesity-predisposing change that fits well with the USF1-associated pathology. In addition to this evidence, the possible role of genetic variation of ACACB in human obesity is an attractive hypothesis, given the results of a large genome scan for obesity (Nϭ1297 from 260 European American families) in which the most significant linkage was observed on chromosome 12q23-24 directly overlying the ACACB locus. 38 Another interesting observation was the significantly lower transcript levels of ATP-binding cassette A1 (ABCA1) among the risk-allele carriers, consistent with our earlier report. 22 Loss of function mutations in ABCA1 result in Tangier's disease and familial hypoalphalipoproteinemia characterized by low-HDL levels and an increased risk for coronary heart disease. 39 Consistent with this observation, the lower expression of ABCA1 in the adipose tissue of the risk-allele carriers was associated with lower HDL levels (Pϭ0.019). A similar trend between usf1s2 genotype and HDL was observed in the twin sample, but it did not reach statistical significance.
In general, lessons in the study of complex diseases may be learned from the apparent mechanism by which USF1associated dyslipidemia arises. Namely, it may not be sufficient to interrogate only simple phenotypes such as fasting lipids concentrations. Rather, attention needs also to be paid to dynamic changes during metabolic challenges, such as insulin challenge or oral glucose tolerance tests. Even on finding the most likely functional variant, the dysfunction may become apparent only in specific environmental conditions. This fits well with the genes-environment cross talk implied in most complex traits.
With the current findings, it seems a likely explanation that in carriers of the risk allele at usf1s2, no measurable change in USF1 exists at steady state, but in the hyperinsulinemic state, their suboptimal transcriptional response of USF1 leads only to a limited transcriptional response in the target genes. It is conceivable that this weaker response in a postprandial state with time can lead to the permanent changes that we see in individuals who develop dyslipidemia and heart disease.
